Sonoma Pharmaceuticals Expands ATM Program to $3.6M, Reports $574K in Recent Stock Sales
SNOA sits 35% above its 52-week low of $0.85 on light trading volume (0.3× avg).
Summary
Sonoma Pharmaceuticals has expanded its At-The-Market (ATM) equity offering program to $3.6 million and reported selling $574,633 worth of common stock since September 2025, significantly increasing potential future dilution.
Key Events · Financing and Capital Events · SNOA
-
ATM Program Expansion
The company increased its At-The-Market (ATM) equity offering program from an initial $2.07 million to a total aggregate offering price of $3.64 million.
-
Recent Stock Sales Reported
Sonoma Pharmaceuticals sold an aggregate of 173,073 shares of common stock for $574,633 under the ATM program between September 26, 2025, and June 18, 2026.
-
Significant Dilution Potential
The expanded ATM program, with $3.64 million available for future sales, represents a substantial portion of the company's current market value, indicating significant potential dilution if fully utilized.
-
Addressing Financial Challenges
This capital raise is critical for the company, which recently reported severe financial challenges and a high cash burn in its latest 10-K filing.
Analysis · SNOA · Industrial Applications And Services
This filing updates an existing At-The-Market (ATM) program, revealing that the company has already sold a substantial amount of stock relative to its market capitalization. The expansion of the program to $3.6 million, representing a significant portion of the company's current market value, indicates a continued need for capital and creates a substantial overhang for existing shareholders. This follows the recent 10-K filing which highlighted severe financial challenges and a high cash burn, making this dilutive capital raise critical for extending the company's operational runway.
At the time of this filing, SNOA was trading at $1.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.85 to $6.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.